Calidi Biotherapeutics, Inc.(CLDI)Earnings, Financials & Key Ratios
CLDI•AMEX
Price updated Jun 19, 2026
AboutCalidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$20M+27.0%
- Net Income-$22M+24.2%
- EPS (Diluted)-35.70+82.8%
- ROE-1125.15%
CLDI Key Insights
Calidi Biotherapeutics, Inc. (CLDI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗High debt to equity ratio of 3.6x
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLDI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLDI Price & Volume
Calidi Biotherapeutics, Inc. (CLDI) stock price & volume — 10-year historical chart
Loading chart...
CLDI Growth Metrics
Calidi Biotherapeutics, Inc. (CLDI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.46%
Return on Capital
10 Years-973.66%
5 Years-973.66%
3 Years-973.66%
Last Year-973.66%
CLDI Peer Comparison
Calidi Biotherapeutics, Inc. (CLDI) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ONCY | 107.8M | 0.96 | -3.30 | -102.46% | ||||
 CGEN | 190.05M | 2.01 | 5.29 | 161.14% | 48.57% | 55.68% | 0.03 | |
 VVOS | 2.94M | 0.50 | -0.24 | 16.05% | -128.36% | -23.38% | ||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare CLDI vs Peers
Calidi Biotherapeutics, Inc. (CLDI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLDI Income Statement
Calidi Biotherapeutics, Inc. (CLDI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 449K | 45K | 0 | 0 | 0 |
Revenue Growth % | - | - | -89.98% | -100% | - | - |
Cost of Goods Sold | 0 | 94K | 274K | 1.26M | 0 | 820K |
COGS % of Revenue | - | 20.94% | 608.89% | - | - | - |
Gross Profit | 0▲ 0% | 355K▲ 0% | -229K▼ 164.5% | -1.26M▼ 448.5% | 0▲ 100.0% | -820K▲ 0% |
Gross Margin % | - | 79.06% | -508.89% | - | - | - |
Gross Profit Growth % | - | - | -164.51% | -448.47% | 100% | - |
Operating Expenses | 6.77M | 10.84M | 22.9M | 27.74M | 21.78M | 18.98M |
OpEx % of Revenue | - | 2413.59% | 50886.67% | - | - | - |
Selling, General & Admin | 3.59M | 6.16M | 15.64M | 15.98M | 12.9M | 9.79M |
SG&A % of Revenue | - | 1372.61% | 34760% | - | - | - |
Research & Development | 3.18M | 4.67M | 7.26M | 13.01M | 8.88M | 9.19M |
R&D % of Revenue | - | 1040.98% | 16126.67% | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | -1.26M | 0 | 0 |
Operating Income | -6.77M▲ 0% | -10.48M▼ 54.8% | -23.13M▼ 120.6% | -28.99M▼ 25.4% | -21.78M▲ 24.9% | -19.8M▲ 0% |
Operating Margin % | - | -2334.52% | -51395.56% | - | - | - |
Operating Income Growth % | - | -54.76% | -120.64% | -25.35% | 24.89% | - |
EBITDA | -6.67M | -10.33M | -22.87M | -27.74M | -20.24M | -18.18M |
EBITDA Margin % | - | -2299.78% | -50817.78% | - | - | - |
EBITDA Growth % | - | -54.91% | -121.46% | -21.29% | 27.02% | 30.25% |
D&A (Non-Cash Add-back) | 107K | 156K | 260K | 1.26M | 1.53M | 1.62M |
EBIT | -6.77M | -9.61M | -25.26M | -25.45M | -21.26M | -19.79M |
Net Interest Income | -163K | -614K | -158K | -3.75M | -933K | -340K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 163K | 614K | 158K | 3.75M | 933K | 340K |
Other Income/Expense | -1.16M | 13.88M | -2.29M | -208K | -419K | -332K |
Pretax Income | -7.93M▲ 0% | 3.4M▲ 142.8% | -25.42M▼ 848.0% | -29.2M▼ 14.9% | -22.2M▲ 24.0% | -20.13M▲ 0% |
Pretax Margin % | - | 756.74% | -56480% | - | - | - |
Income Tax | 4K | 11K | 11K | 16K | 14K | 20K |
Effective Tax Rate % | -0.05% | 0.32% | -0.04% | -0.05% | -0.06% | -0.1% |
Net Income | -7.94M▲ 0% | -10.93M▼ 37.7% | -25.43M▼ 132.6% | -29.22M▼ 14.9% | -22.14M▲ 24.2% | -19.95M▲ 0% |
Net Margin % | - | -2434.97% | -56504.44% | - | - | - |
Net Income Growth % | - | -37.75% | -132.57% | -14.9% | 24.21% | 24.08% |
Net Income (Continuing) | -7.94M | 3.39M | -25.43M | -29.22M | -22.21M | -20.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 434K | 280K |
EPS (Diluted) | -2.64▲ 0% | 14.16▲ 636.4% | -358.80▼ 2633.9% | -207.61▲ 42.1% | -35.70▲ 82.8% | -4.07▲ 0% |
EPS Growth % | - | 636.36% | -2633.9% | 42.14% | 82.8% | 87.46% |
EPS (Basic) | -2.64 | 14.16 | -358.80 | -207.61 | -35.70 | - |
Diluted Shares Outstanding | 2.98M | 238.63K | 70.59K | 140.16K | 664.41K | 4.91M |
Basic Shares Outstanding | 2.98M | 238.63K | 70.59K | 140.16K | 664.41K | 4.91M |
Dividend Payout Ratio | - | - | - | - | - | - |
CLDI Balance Sheet
Calidi Biotherapeutics, Inc. (CLDI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 513K | 2.74M | 786K | 4.3M | 10.23M | 11.03M |
Cash & Short-Term Investments | 420K | 2.14M | 372K | 2.05M | 9.59M | 10.38M |
Cash Only | 420K | 2.14M | 372K | 2.05M | 9.59M | 10.38M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 1.36M | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 93K | 100K | 303K | 125K | 249K | 653K |
Total Non-Current Assets | 1.34M | 651K | 1.81M | 5.72M | 3.96M | 3M |
Property, Plant & Equipment | 723K | 585K | 1.09M | 5.34M | 2.93M | 2.01M |
Fixed Asset Turnover | - | 0.77x | 0.04x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 230K | 129K | 354K |
Other Non-Current Assets | 616K | 66K | 725K | 143K | 892K | 989K |
Total Assets | 1.85M▲ 0% | 3.39M▲ 83.1% | 2.6M▼ 23.4% | 10.02M▲ 285.8% | 14.18M▲ 41.6% | 14.03M▲ 0% |
Asset Turnover | - | 0.13x | 0.02x | - | - | 0.00x |
Asset Growth % | - | 83.1% | -23.41% | 285.79% | 41.55% | 301.13% |
Total Current Liabilities | 8.89M | 25.96M | 42.99M | 10.23M | 9.5M | 5.19M |
Accounts Payable | 822K | 624K | 2.12M | 2.88M | 2.07M | 1.14M |
Days Payables Outstanding | - | 2.42K | 2.83K | 836.07 | - | 627.62 |
Short-Term Debt | 4.94M | 5M | 5.42M | 807K | 3.18M | 2.28M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.1M | 16.69M | 29.83M | 0 | 2K | 1.77M |
Current Ratio | 0.06x | 0.11x | 0.02x | 0.42x | 1.08x | 2.12x |
Quick Ratio | 0.06x | 0.11x | 0.02x | 0.42x | 1.08x | 2.12x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 15.44M | 43K | 10.05M | 8.02M | 2.72M | 1.64M |
Long-Term Debt | 6.37M | 0 | 0 | 2.06M | 600K | 837K |
Capital Lease Obligations | 72K | 43K | 447K | 3.25M | 1.99M | 4.86M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9M | 0 | 9.6M | 2.71M | 128K | 801K |
Total Liabilities | 24.33M | 26M | 53.04M | 18.25M | 12.21M | 6.83M |
Total Debt | 11.72M | 5.18M | 5.99M | 7.24M | 7.04M | 3.11M |
Net Debt | 11.3M | 3.04M | 5.62M | 5.19M | -2.56M | -7.26M |
Debt / Equity | - | - | - | - | 3.58x | 0.43x |
Debt / EBITDA | - | - | - | - | - | -0.17x |
Net Debt / EBITDA | - | - | - | - | - | 0.40x |
Interest Coverage | -41.55x | -17.07x | -146.38x | -7.73x | -23.34x | -58.21x |
Total Equity | -22.48M▲ 0% | -22.61M▼ 0.6% | -50.44M▼ 123.1% | -8.23M▲ 83.7% | 1.97M▲ 123.9% | 7.2M▲ 0% |
Equity Growth % | - | -0.58% | -123.08% | 83.67% | 123.9% | 565.11% |
Book Value per Share | -7.54 | -94.76 | -714.54 | -58.75 | 2.96 | 1.47 |
Total Shareholders' Equity | -22.48M | -22.61M | -50.44M | -8.23M | 1.53M | 6.92M |
Common Stock | 2K | 2K | 2K | 4K | 2K | 1K |
Retained Earnings | -34.44M | -44.93M | -70.36M | -99.57M | -121.72M | -137.56M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 6K | -1K | -14K | -47K | -28K | -13K |
Minority Interest | 0 | 0 | 0 | 0 | 434K | 280K |
CLDI Cash Flow Statement
Calidi Biotherapeutics, Inc. (CLDI) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -4.83M | -7.77M | -13.21M | -26.98M | -19.69M | -21.67M |
Operating CF Margin % | - | -1731.4% | -29364.44% | - | - | - |
Operating CF Growth % | - | -61.09% | -69.98% | -104.2% | 27.01% | -103.78% |
Net Income | -7.94M | -10.93M | -25.43M | -29.22M | -22.21M | -19.95M |
Depreciation & Amortization | 184K | 153K | 260K | 1.26M | 1.53M | 1.62M |
Stock-Based Compensation | 968K | 1.33M | 0 | 4.81M | 2.96M | 1.75M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.01M | 582K | 8.38M | 2.41M | -279K | 537K |
Working Capital Changes | 945K | 1.1M | 3.57M | -6.24M | -1.7M | -5.46M |
Change in Receivables | 0 | 0 | -870 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 293K | -239K | 1.62M | -6.17M | -628K | -2.09M |
Cash from Investing | -388K | -215K | -494K | -478K | -16K | -96K |
Capital Expenditures | -351K | -206K | -428K | -585K | 0 | -96K |
CapEx % of Revenue | - | 45.88% | 951.11% | - | - | - |
Acquisitions | 0 | 0 | 0 | 9K | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | -37K | -9K | -190.08M | 98K | -16K | 0 |
Cash from Financing | 4.7M | 9.81M | 12.09M | 29.04M | 27.36M | 30.23M |
Debt Issued (Net) | 1.88M | 1.75M | 1.38M | 899K | 1.92M | -2.8M |
Equity Issued (Net) | 2.82M | 35K | 10.76M | 27.26M | 18.07M | 31.97M |
Dividends Paid | 0 | 0 | 0 | 0 | -1.67M | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -4K | 8.03M | -58K | 885K | 9.05M | 1.06M |
Net Change in Cash | -514K▲ 0% | 1.82M▲ 453.5% | -590.65K▼ 132.5% | 1.58M▲ 367.0% | 7.64M▲ 384.6% | 8.36M▲ 0% |
Free Cash Flow | -5.18M▲ 0% | -7.98M▼ 54.1% | -13.64M▼ 71.0% | -27.57M▼ 102.1% | -19.71M▲ 28.5% | -21.77M▲ 0% |
FCF Margin % | - | -1777.28% | -30315.56% | - | - | - |
FCF Growth % | - | -54.14% | -70.95% | -102.08% | 28.5% | -21.75% |
FCF per Share | -1.74 | -33.44 | -193.25 | -196.69 | -29.67 | -4.44 |
FCF Conversion (FCF/Net Income) | 0.61x | 0.71x | 0.52x | 0.92x | 0.89x | 1.09x |
Interest Paid | 20K | 45K | 0 | 404K | 140K | 853K |
Taxes Paid | 2K | 8K | 0 | 11K | 14K | 11K |
CLDI Key Ratios
Calidi Biotherapeutics, Inc. (CLDI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -1125.15% | -430.33% |
Return on Invested Capital (ROIC) | - | - | - | - | -3712.5% |
Gross Margin | 79.06% | -508.89% | - | - | - |
Net Margin | -2434.97% | -56504.44% | - | - | - |
Debt / Equity | - | - | - | 3.58x | 0.43x |
Interest Coverage | -17.07x | -146.38x | -7.73x | -23.34x | -58.21x |
FCF Conversion | 0.71x | 0.52x | 0.92x | 0.89x | 1.09x |
Revenue Growth | - | -89.98% | -100% | - | - |
Related:CLDI Dividend History·CLDI Revenue History·CLDI Price History·CLDI P/E History·CLDI Financial Ratios·CLDI Institutional Holders
CLDI Frequently Asked Questions
Calidi Biotherapeutics, Inc. (CLDI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Calidi Biotherapeutics, Inc. (CLDI) grew revenue by 0.0% over the past year. Growth has been modest.
Calidi Biotherapeutics, Inc. (CLDI) reported a net loss of $19.9M for fiscal year 2024.
Dividend & Returns
Yes, Calidi Biotherapeutics, Inc. (CLDI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Calidi Biotherapeutics, Inc. (CLDI) has a return on equity (ROE) of -1125.2%. Negative ROE indicates the company is unprofitable.
Calidi Biotherapeutics, Inc. (CLDI) had negative free cash flow of $21.8M in fiscal year 2024, likely due to heavy capital investments.